Table 1 Interaction between lncRNAs and KRAS in the context of cancer (ANTs: adjacent normal tissues)
From: Emerging role of non-coding RNAs in the regulation of KRAS
lncRNA | Cancer subtype | Pattern of expression | Samples | Cell line | Targets/regulators | Signaling pathways | Function | References |
|---|---|---|---|---|---|---|---|---|
Orilnc1 | Different cancer cell lines | Up | Female nude mice | MDA-MB-231, MDA-MB-435, MCF10A, IMR90, SK-MEL-2 and LOX-IMVI | AP1, Cyclin E1 | RAS-RAF-MEK-ERK signaling cascade | Orilnc1 expression enhanced cancer cell growth represses G1/S arrest | [14] |
KIMAT1 | Lung cancer | Up | 75 tumors and matched ANTs and PDX mouse model | H1299, H460, A549, H1975, CALU1 and CALU6, lung squamous cell carcinoma cell line H520, lung fibroblasts HEL299, lung bronchial epithelial cell line HBEC3-KT | DHX9 and NPM1 | KRAS signaling | KIMAT1 enhanced cancer cell survival, growth and invasion | [15] |
SLCO4A1-AS1 | Colorectal cancer | Up | 45 pairs of CRC tissues and ANTs | HT29 and SW480 | – | KRAS/EGFR/MAPK signaling pathway | SLCO4A1-AS1 induced CRC cell proliferation, migration and invasion | [16] |
LINC01420 | Pancreatic cancer | Up | BALB/c nude mice | HPDE6-C7, PANC-1, SW1990, HPAC, CFAPC-1, and BxPC-3 and HEK-293T | MYC/miR-494-3p | K-RAS signaling | LINC01420 enhanced cancer cell proliferation and PC EMT and induced PC tumor growth in vivo | [17] |
KRAS1P | Prostate cancer | Up | – | DU145 | KRAS | – | KRAS1P 3′UTR functions as endogenous microRNA decoy and plays putative proto-oncogenic role | [18] |
YWHAE | Colorectal cancer | Up | 6 colorectal normal and 10 colorectal cancer tissues | HT29, HCT116, SW480 and HEK293-T cells | miR-323a-3p and miR-532-5p | K-Ras /Erk1/2 and PI3K/Akt signaling pathways | YWHAE enhances cell cycle progression cell migration | [19] |
PART1 | Non-small cell lung cancer | Up | – | BEAS-2B, NCI-H2444, NCI-H647, A549, and NCI-H2 | KRAS | – | Suppression of PART1 sensitizes wild type but not KRAS mutant cells to erlotinib | [20] |
MALAT1 | Prostate cancer | Up | 20 pairs of PC tumor tissues and ANTs | PC3, LNCap, and DU145 | miR-1 | miR-1/KRAS | MALAT1 induced proliferation and inhibited apoptosis in PC cells | [21] |
PCAT-1 | Lung chemoresistance | Up | Tumor samples and ANTs from 96 lung cancer patients | A549, H1975 | p27/CDK6 | miR-182/miR-217 signaling/K-RAS | Exosomal PCAT-1 induced tumor growth and guides lymph node metastasis | [22] |
lncRNA-NUTF2P3-001 | Pancreatic cancer | Up | 30 pancreatic cancer, 10 chronic pancreatitis and 30 noncancerous pancreatic tissues | PANC-1 and BXPC-3 | miR-3923 | miR-3923/KRAS pathway | lncRNA-NUTF2P3-001 enhanced viability, proliferation and invasion | [23] |
TP53TG1 | Pancreatic ductal adenocarcinoma (PDAC) | Up | 95 pairs of PDAC tissues and ANTs | PANC-1, MIA PaCa-2, BxPC-3 | miR-96 and KRAS | – | TP53TG1 promoted proliferation, inhibited apoptosis, and increased migration and invasion in PDAC cells | [24] |